Elevation Oncology, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Elevation Oncology, Inc. | ELEV - NASDAQ |
$15.00-$17.00 | $16.00 | $14.00 | 6.25 million | 6/25/2021 |
| JP Morgan, Cowen, SVB Leerink | ||||||
Co-Manager(s): Wedbush PacGrow | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-06-04 Terms Added 2021-06-21 | ||||||
Elevation Oncology, Inc. Quote & Chart - Click for current quote - ELEV
IPO Boutique aggregates information on public companies and private companies, such as "ELEV" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Elevation Oncology, Inc. (adapted from Elevation Oncology, Inc. prospectus):
They are a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ELEV" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.